POMDOCTOR LIMITED Announces Termination of ADR Program and Direct Listing on Nasdaq
POMDOCTOR LIMITED (NASDAQ: POM) has announced the termination of its American Depositary Receipt (ADR) program, which will be completed by October 21, 2026. The company's Class A ordinary shares are expected to begin trading directly on Nasdaq under the same ticker symbol 'POM' following a mandatory exchange and share consolidation process. The termination of the ADR program was approved by both the board of directors in September 2026 and shareholders at an extraordinary general meeting. As part of this transition, every ten ADSs will be converted into three Class A ordinary shares after a 10-to-1 share consolidation. The company has appointed TranShare Corporation as its U.S. transfer agent for these new shares. This move reflects Pomdoctor's strategy to streamline operations and align with evolving healthcare trends by leveraging AI, wearable technologies, and data-driven services.
Tickers: $POM
Topics: AI-enabled solutions digital healthcare stock market